Standards of care and the burden of treatment failure in type 2 diabetes.
Despite the armamentarium of oral and injectable agents available for the treatment of type 2 diabetes, there is clearly a significant gap between current recommendations for glycemic targets and the proportion of patients who can achieve and maintain glycemic control. Early diagnosis and intervention, particularly with the initiation of insulin therapy, may delay the progressive loss of pancreatic beta cells and the risk for macrovascular and microvascular complications. While there are numerous myths and misconceptions surrounding insulin therapy, physician and patient education, as well as an awareness of cultural sensitivities, can be instrumental in overcoming these barriers.
James Madison University PA Program, USA.
B Scott
BS
Urquhart
D000284:Administration, Oral; D001294:Attitude to Health; D001786:Blood Glucose / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D018450:Disease Progression; D006801:Humans; D006943:Hyperglycemia / Q000517:prevention & control; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D007279:Injections, Subcutaneous / Q000523:psychology; D007328:Insulin / Q000097:blood / Q000627:therapeutic use*; D010817:Physician-Patient Relations; D017211:Treatment Failure
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin